NEOK002 to Begin Clinical Trials in 2026
BEIJING — Biocytogen Pharmaceuticals has announced the FDA’s approval for an investigational new drug (IND) application for NEOK002, a treatment targeting solid tumors. The company plans to initiate Phase 1 clinical trials in mid-2026, with data expected by 2027. This marks a significant milestone in Biocytogen’s efforts to advance cancer treatment options.
NEOK002, developed using Biocytogen’s proprietary RenLite® platform, targets the EGFR/MUC1 pathways to potentially improve efficacy and safety over existing therapies. This innovative approach signifies a major advancement in the field of oncology, offering new hope for patients with limited treatment options. The development of NEOK002 underscores the importance of cutting-edge research and collaboration in the biotech industry.
According to NEOK Bio, the drug’s design is anticipated to provide a dual-action mechanism that enhances its therapeutic potential. The drug’s progress is a significant step for the candidate, originally developed by Biocytogen and licensed in 2024, affirming the company’s commitment to addressing unmet medical needs.
Biocytogen’s Innovative Approach
Dr. Yuelei Shen, President and CEO of Biocytogen, expressed satisfaction with the progress, stating that this milestone validates their bispecific antibodies’ therapeutic potential. Biocytogen’s RenLite® platform has been pivotal in developing these solutions. The approval of NEOK002 not only strengthens Biocytogen’s position in the biotech industry but also highlights the growing importance of bispecific antibodies in cancer treatment.
Biocytogen, a leader in antibody-based drug development, combines a comprehensive antibody library with a target-humanized mouse model portfolio to accelerate drug discovery. The company continues to expand its partnerships and research capabilities globally, aiming to bring innovative therapies to market more efficiently. With a commitment to improving patient outcomes, Biocytogen remains at the forefront of biopharmaceutical innovation.
